Magnevist

Gadopentetate dimeglumine, the active ingredient in Magnevist, is a gadolinium-based contrast agent presented as a 0.5 mmol/mL injection solution for intra‑articular use. It enhances magnetic resonance imaging (MRI) signal intensity to aid diagnostic visualization in patients undergoing imaging studies.

GNH USA supplies Magnevist as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Magnevist (gadopentetate dimeglumine) is used as a contrast agent in magnetic resonance imaging (MRI) to improve visualization of anatomical structures.

- Central nervous system imaging: improves detection of lesions, tumors, and vascular abnormalities. - Musculoskeletal imaging: enhances visualization of joints, cartilage, and soft‑tissue pathology. - Cardiovascular imaging: facilitates assessment of cardiac chambers, vessels, and perfusion. - Abdominal and pelvic imaging: aids in delineating liver lesions, tumors, and inflammatory disease.

Magnevist may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild and transient. - Headache: occasional during or after injection. - Injection site discomfort: mild pain or burning sensation. - Warmth or flushing: brief sensation of heat.

Serious or Rare Side Effects: - Nephrogenic systemic fibrosis: rare fibrotic disorder in patients with severe renal impairment. - Severe allergic reaction: anaphylaxis or hypersensitivity requiring immediate medical attention. - Acute kidney injury: rapid decline in renal function, particularly in at‑risk patients. - Cardiovascular events: hypotension or arrhythmia observed in rare cases.

Prior to administration, several safety considerations should be observed.

- Renal function assessment: evaluate kidney function before administration. - Pregnancy: use only if benefit outweighs risk (Category C). - Hydration: ensure adequate patient hydration to facilitate renal clearance. - Allergy history: screen for prior gadolinium or contrast media reactions. - Concurrent nephrotoxic drugs: avoid or monitor closely. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Magnevist may interact with other agents affecting renal function or contrast safety.

Major Interactions (Avoid): - Severe renal impairment: contraindicated due to risk of nephrogenic systemic fibrosis. - High‑dose iodinated contrast within 24 hours: increased risk of renal toxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics: may affect renal clearance, monitor kidney function. - Nephrotoxic antibiotics (e.g., aminoglycosides): monitor renal function. - ACE inhibitors/ARBs: may influence renal perfusion, observe closely.